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Introduction
The clinical course of multiple sclerosis (MS) is diverse and 
unpredictable: Some people develop rapidly evolving neuro-
logical deficits, whereas others accrue little or no detectable 
neurological deficit over decades1. Magnetic resonance imaging 
(MRI) is now firmly established as a key tool in the diagnosis 
of MS2, based on its ability to show white matter (WM) lesions 
with a typical spatial and temporal distribution for MS. However, 
the number and volume of WM lesions explain only a small 
fraction of the diversity of clinical outcomes in MS, and this 
mismatch has been termed the clinico-radiological paradox3.
This apparent paradox would matter less if we had clinical tools 
that were able to sensitively and reliably measure MS progression; 
however, scores such as the Expanded Disability Status Scale 
(EDSS) have well-recognised limitations4, one of which is rela-
tively limited sensitivity to change in individuals. Some MRI 
measures are much more sensitive to change, but their clinical 
relevance is debated, in part due to the clinico-radiological 
paradox. Despite this, and because of greater sensitivity to change, 
MRI is now routinely used as the primary outcome in early phase 
treatment trials. While associations between the accrual of WM 
lesions and MS relapses are modest, it has been shown that a 
treatment effect seen on WM lesion accrual is a good predictor of 
the likely effects on relapses5.
The clinico-radiological paradox has also assumed a greater rel-
evance with the advent of treatments that suppress relapses and, 
very recently, slow progression. Given the limited sensitivity 
of clinical measures for ongoing disease activity, there has been 
increasing interest in using composite clinical and MRI measure of 
disease activity and treatment efficacy (for example, ‘no evidence 
of disease activity’ assessments based on relapses, clinical progres-
sion and MRI measures of new lesion formation). However, in this 
regard, low levels of MRI-apparent disease activity may not (on 
their own) be associated with a substantial risk of further clinical 
events6.
Understanding the clinico-radiological paradox is important in 
the search for more sensitive and specific surrogates of relapses 
and disability progression (such that they can be used to inform 
treatment choices in individual people with MS) and to gain a 
better understanding of the pathophysiological basis of disabil-
ity in MS (to identify and assess key therapeutic targets). In this 
brief review, we will consider themes and issues underlying the 
clinico-radiological paradox and recent advances in its resolution.
Pathological abnormalities in multiple sclerosis
The pathological effects of MS are multifaceted and variable, 
and the location, nature, extent and intensity of pathology are all 
relevant to clinical outcomes. While the most conspicuous abnor-
mality is the presence of demyelinating lesions in WM, there is 
much more to the pathology of MS than WM lesions. Grey matter 
(GM) lesions are seen throughout the course of MS7 and, in people 
with long-standing progressive MS, may actually be more exten-
sive than lesions in WM8. Extra-lesional tissues are also abnormal 
with, for example, glial abnormalities and reduced axonal densities 
seen in WM9 and glial abnormalities, and loss of dendrites 
and neurons, in GM (for example, 10). Lesions themselves are 
heterogeneous, sufficiently so that WM subtypes have been 
defined11, and within lesions there may be differing degrees of 
inflammation, demyelination and remyelination, and axonal loss, 
all of which may influence their functional consequences. Pathol-
ogy in MS is also not spatially uniform. Demyelinating lesions 
tend to form around the lateral ventricles12, and GM lesions occur 
most often in the cortical layers close to the surface of the brain8. 
Neurodegeneration also affects some regions more than others 
(for example, retrograde neurodegeneration may preferentially 
affect deep GM)13. Elements of MS pathology (for example, brain 
WM lesion loads) can vary substantially among people with MS, 
even when they have seemingly similar clinical outcomes.
Measurement characteristics
When we measure, we do so with varying degrees of overlying 
noise and underlying specificity, both of which can significantly 
reduce the apparent strength of associations between measures. 
When we repeat a measure, it is usual to observe variations in the 
results; whereas some of this variation may be due to a change 
in what is being measured, some will be due to measurement 
error; and with increasing measurement errors, apparent asso-
ciations between measures can be attenuated (Figure 1). This can 
lead us to underestimate the clinical relevance of a pathological 
feature being assessed by using MRI. Similarly, the specificity of a 
measure can significantly affect associations: Few (if any) MRI 
or clinical measures reflect only one biological feature or its 
associated functional outcome, although some are more specific 
than others (see below).
Clinical measures
Clinical measures in MS seek to assess either the frequency of 
events over a given period (for example, relapse rate) or the level 
of neurological impairment at a given time. The most frequently 
assessed clinical measure of disease activity is the relapse rate. 
However, this has a number of limitations. It reflects new inflam-
matory lesions in clinically eloquent regions only, and lesions in 
other areas will go undetected. The estimation of a relapse rate is 
also open to recall bias (particularly where events are not recorded 
at the time of their occurrence), inter-observer variability (as each 
clinician may apply different clinical thresholds), and other factors 
such as silent infection, fatigue and low mood which can give rise 
to pseudo-relapses (that is, a transient worsening of symptoms that 
is not due to new inflammatory activity)14.
With regard to measures of neurological impairment, the EDSS15 
is the most widely used measure of disability in MS. It produces 
a score based on symptoms and signs in eight functional systems, 
walking ability and activities of daily living. Scores are on an ordi-
nal scale from 0 (asymptomatic with normal examination) to 10 
(death due to MS). Scores of 0–3.5 reflect neurological impairment 
without a clear effect on mobility, 4–7.5 reflects impaired mobility, 
and 8–9.5 reflects effects on activities of daily living. Though easy 
to record and widely used, it has several limitations. For an ordinal 
scale measurement, parametric statistics should not be used with-
out assessing whether the underlying assumptions of such statistics 
have been significantly breached, and non-parametric statistics are 
often preferred albeit with a potential loss of statistical power. It 
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is also open to intra- and inter-variability when scoring, particu-
larly with scores of less than 416. Since its initial description, it has 
become apparent that other frequently occurring—and function-
ally significant—clinical manifestations of MS, such as cognitive 
impairment and fatigue, are relatively overlooked, and therefore it 
is not a true global measure of disability4.
To address some of the limitations of the EDSS, the Multiple Scle-
rosis Functional Composite (MSFC) was developed17. It assesses 
three important functional domains: ambulation (timed 25-foot 
walk), upper limb function (nine-hole peg test) and cognition 
(paced auditory serial addition task, or PASAT)17. The results from 
each component are converted to a z-score based on values from 
a reference population, thus producing continuous rather than 
ordinal data. The MSFC has good intra- and inter-rater reliability 
and, importantly, also more explicitly assesses cognition. How-
ever, there is debate about whether to use the MSFC score or its 
components separately. Combining domains provides a relative 
assessment of the clinical effects of MS; but, unlike the EDSS 
score, it does not provide an easily interpretable measure of disabil-
ity; for example, an EDSS score of 3.5 means that mobility is not 
impaired, whereas an MSFC z-score of 3.5 does not do so. In addi-
tion, small but significant changes in any of the domains may be 
diluted and so overlooked. Given that each domain included in the 
MSFC may be influenced to a greater or lesser degree by different 
aspects of MS pathology (for example, cortical neurodegeneration 
may be more relevant to cognitive impairment than motor func-
tion, whereas demyelination or axonal loss may be more relevant to 
motor function than cognitive impairment), the use of more specific 
clinical outcome measures is likely to be more informative when 
investigating pathophysiological mechanisms.
While the MSFC is more comprehensive in its assessment of 
disability than the EDSS, there is still scope for this to be improved 
on. The PASAT has some practical drawbacks such as a require-
ment for mathematical skills, a ceiling effect, and it is disliked 
by test subjects. Furthermore, it does not encompass all aspects 
of cognitive function. Other measures of cognitive dysfunction 
have been proposed. The Symbol Digit Modalities Test (SDMT) 
measures information-processing speed and is more easily 
administered, better tolerated, and more reliable than the PASAT18. 
Building on the SDMT, a brief international cognitive assess-
ment for MS (BICAMS) has been proposed which includes the 
SDMT with the addition of the California Verbal Learning Test 
and the Brief Visuospatial Memory Test19. This attempts to assess 
other aspects of cognitive dysfunction. The MSFC also does not 
assess domains such as vision and bladder or bowel function, 
which can also have substantial effects on the lives of people with 
MS4.
While the EDSS is not an ideal measure of the neurological effects 
of MS, it remains the most popular disability score in clinical prac-
tice, and pragmatically (owing to service constraints) it would be 
difficult to incorporate a more extensive assessment in most health-
care settings. In clinical trials, while there may be more scope to 
use additional clinical outcome measures, for new treatments to be 
licensed these would have to be accepted by regulatory authorities 
as being valid markers of efficacy.
Figure 1. Simulated perfectly correlated data, with a mean of 51 and a standard deviation (SD) of 15.1. Clockwise from the top left: No 
added noise, r = 1; noise SD = 5, r = 0.89; noise SD = 7.5, r = 0.59; and noise SD = 10, r = 0.33.
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Magnetic resonance imaging measures
MRI measures can be broadly divided into those that assess 
macro-structure (for example, brain volumes), micro-structure 
(for example, magnetisation transfer imaging and diffusion tensor 
imaging, or DTI), metabolic features (such as proton spectroscopy 
and perfusion) and function (functional MRI, or fMRI)20. Here, to 
illustrate points, we will consider these in outline only.
As with pathological studies, WM lesions in MS are the most con-
spicuous abnormality on conventional MRI scans. The majority of 
WM lesions seen on histopathological examination are also identi-
fied on MRI, and about 60% are seen on T2-weighted scans and 
70% on T2 fluid-attenuated inversion recovery (FLAIR) scans21. 
Though more extensive, GM lesions are much more difficult to 
identify on these scans; less than 5% of cortical lesions are seen 
on T2-weighted scans, and 5% on T2-FLAIR; for deep GM, about 
15% and 40% respectively are seen21. Double inversion recovery 
improves on this; about 10% of cortical and deep GM lesions are 
detected22, and phase-sensitive inversion recovery may increase this 
further23. However, while subpial GM lesions are the most exten-
sive type seen histopathologically, they are rarely identified using 
MRI at 3T. MRI at higher field strengths, such as 7T, appears to 
improve on this24 but currently is not widely available in clinical 
practice or for research. Seewann and colleagues have shown (at 
1.5T) that the GM lesions detected using MRI are the ‘tip of the 
pathological iceberg’, differing in size rather than other patho-
logical characteristics from those that go undetected25. Practically, 
when correlations of lesions measures with clinical outcomes are 
considered, it is likely—given lower sensitivity to GM compared 
with WM lesion—that the clinical relevance of GM lesions (in par-
ticular subpial lesions) will be underestimated when compared with 
WM lesions.
It is well recognised that lesions may be pathologically diverse 
but can appear similar on MRI scans. For example, without the 
use of a contrast agent, it is not possible to determine whether a 
lesion is actively inflamed and demyelinating, chronically demy-
elinated or remyelinating. However, not all lesions seen on a 
T2/proton density-weighted scan are seen on a T1-weighted 
image, and the subset of lesions seen on T1-weighted scans appear 
to represent those that have sustained greater axonal injuries26. 
Despite this, correlations of T2-weighted and T1-weighted WM 
lesion loads with clinical outcomes are similar27, suggesting that the 
difference in axonal loss between these lesions is either of limited 
clinical relevance or that other factors (such as measurement errors) 
mask any additional contribution axonal loss may make (beyond 
demyelination) to the association between lesion measures and 
clinical outcomes.
Brain volume loss, a marker of brain atrophy, which reflects 
neurodegeneration28,29, is an MRI measure that is increasingly 
being used in clinical trials, particularly in progressive MS. 
However, the optimal way to measure brain volume or atrophy 
has yet to be determined, and a variety of approaches have been 
tried30. Methods can be divided into those that measure tissue 
volumes on each MRI scan independently and those that compare 
scans to assess differences. At a whole brain level, methods that 
compare scans (for example, as implemented in Structural Imaging 
Evaluation, using Normalization, of Atrophy, or SIENA) rather 
than assess each scan independently appear to be significantly more 
robust and sensitive to differences31. However, brain volume loss 
does not affect all brain tissues and regions equally; for example, 
there is evidence that it occurs more rapidly in GM than in WM32. 
As such, regional brain volume loss may be diluted in whole brain 
measures, and it has proven challenging to develop regional volume 
measures that can robustly compare scans.
So far, we have considered MRI measures of the quantity of a 
given tissue, but, as noted above, clinically relevant pathological 
abnormalities can affect the quality of tissues too. For example, in 
normal-appearing WM, magnetisation transfer ratio (MTR) and 
DTI measures both have been shown to correlate with disability 
measures33. However, measures of intrinsic tissue characteristics 
are not pathologically specific. For example, MTR correlates not 
only with myelin density but also with axonal density (which itself 
is correlated with myelin density) and gliosis34,35. In progressive 
MS, neurodegeneration is thought to be a (if not the) major process 
responsible for neurological deficits36. While brain atrophy reflects 
neurodegeneration, loss of axons and neurons does not necessarily 
lead to an equivalent reduction in brain volumes: With an accurate 
measure of neuronal and axonal density, we would be able to better 
estimate the actual amount of neurodegeneration rather than a small 
fraction of it.
Most MRI measures used in MS research assess structure, but 
some investigate metabolic and (indirectly) neuronal function. 
Of these, fMRI has been most studied to date but highlights 
the challenges of trying to assess localised neural activity37. 
Neuronal activity occurs at the level of single cells, but fMRI 
works at a much coarser scale (typically several cubic millimetres). 
fMRI also does not assess neuronal activity directly but instead 
via its effects on blood flow and oxygen extraction. Therefore, 
there is a delay between neuronal activity and what is measured 
by fMRI. Other factors (both physiological and pathological) can 
significantly affect blood flow and oxygen extraction and so can 
further decouple fMRI associations with underlying neuronal activ-
ity. There are two main forms of fMRI: task-based (with a subject 
performing a specific activity, such as finger tapping or counting) 
and resting-state (with a subject at rest). These provide differ-
ent information; task-based fMRI probes specific networks (for 
example, motor), whereas resting-state offers a more global but 
less network-specific assessment of brain function37. Interpretation 
of fMRI findings is challenging, as there may be decreased and, 
paradoxically, increased regional activity in MS38. Increased acti-
vation may be adaptive (reducing the functional impact of MS 
pathology) or maladaptive (having no beneficial effect on func-
tion or perhaps even being associated with greater functional 
impairments)39, but these cannot be readily distinguished in cross- 
sectional studies. To determine the dynamic relationship between 
fMRI measures and clinical outcomes, longitudinal studies are 
required to clarify this39.
Linking pathology to clinical outcomes
So far, we have noted technical issues with, and the composite 
nature of, clinical and MRI measures that may attenuate cor-
relations. We have also considered how MS disease effects are 
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not evenly distributed and that regional effects may be diluted in 
whole brain measures and so overlooked. However, we have yet 
to consider the way in which the central nervous system is organ-
ised and in particular how neurological functions rely on the 
integrity of neural networks. This has significant implications for 
the way in which we seek to connect MS pathology with clinical 
outcomes, as pathology within networks may be undervalued in 
whole brain measures (Figure 2). Recognising this, studies have 
looked for associations between regional pathology and clinical 
outcomes. For example, with motor outcomes, it has been shown 
that abnormalities in the cortico-spinal tract are more closely 
linked with function than are measures derived from elsewhere 
in the brain40. Similarly, when compared with whole brain meas-
ures, temporal lobe atrophy has been more closely linked with 
memory impairments41, as has more specific hippocampal 
atrophy42. Another region of particular interest in MS is the 
thalamus, which may be affected directly and through its extensive 
connections with other brain regions43. It has been suggested that, 
owing to its highly connected nature, the thalamus may act as a 
‘barometer’ of MS pathology43. Although we have focused on brain 
measures in this review, it is also clear that pathology anywhere in 
the central nervous system can affect clinical outcomes in MS and 
may do so in addition to abnormalities in the brain (for example, 
spinal cord atrophy44).
Furthermore, connectomics studies have started to model the 
integrity of networks from MRI data (that is, the ability for neu-
ral networks to transfer and process information and so deliver a 
functional outcome)45. Rather than treating a network as a region 
and using MRI to measure pathological effects averaged across it, 
investigators assess elements of the network separately and treat 
them as components, each of which has a different contribution 
to functional outcomes. Graph theory45 provides a mathematical 
framework with which to model overall network characteristics 
on the basis of brain regions and the connection between them. 
A variety of measures can be derived from a graph theory analy-
sis, and it has yet to be determined which measure (or measures) 
best represents the effects that pathology has on function. Despite 
this uncertainly and complexity, such analyses have already 
shown some promise in MS. For example, correlations of EDSS 
with network efficiency (calculated using DTI measures from 
motor network tracts, Spearman r = −0.52) are noticeably greater 
than correlations of EDSS with conventional MRI measures (log 
T2 lesion load r = 0.27 or brain volumes r = −0.30)46. Associa-
tions of network efficiency with EDSS appear to increase further 
 when two measures of tissue microstructure (DTI and MTR) are 
combined (r = −0.77).
In addition to structural MRI measures in MS, graph theory has 
been applied to functional measures such as fMRI (for example, 
disruption of network integrity has been linked with cognitive 
impairment47,48) and magnetoencephalography data (showing 
abnormalities when comparing people with MS and controls49). 
Considering structural and functional assessments of the brain 
together can provide useful insights into the mechanisms underly-
ing disability in MS (for example,38), but combining structural and 
functional measures in a unified assessment of network performance 
has, to the best of our knowledge, not yet been achieved in MS.
Figure 2. Schematic of the brain (light blue), a brain network (dark blue and green) and lesions (red). From left to right: Whole brain 
lesion measures; a region of interest-based assessment of lesions within the network of interest; a network-based assessment of lesions. 
In the whole brain assessment (left), lesion C will have a negligible effect on network performance and so will dilute associations with the 
associated clinical outcome. In a region of interest-based assessment of the network (middle), the effects of lesions A, B and D are considered 
proportional to the volume of the network involved and so may relatively over- or under-value the effects that each lesion has on the associated 
clinical outcome. In the network-based assessment (right), lesions in each brain region (dark blue) or connecting tract (green) are considered 
separately, so allowing the effects on outcomes to be weighted according to their location within the network. For example, lesion B involves 
three tracts and so may have a greater effect on network performance than lesions A and D (each of which affects two tracts).
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Conclusions
Recognition of the clinico-radiological paradox in MS has 
inspired considerable research and has led to a reconsideration of 
MRI and clinical measures and the link between them. Since this 
was first raised, there has been considerable progress on several 
fronts, to a degree that the mismatch between clinical and MRI 
measures is less an unexplained paradox (and so perhaps the term 
‘clinico-radiological paradox’ is increasingly a misnomer) and 
more a potentially reconcilable challenge. From an MRI perspec-
tive, there is growing interest in regional and network-specific 
assessments of pathology and in developing more pathologi-
cally specific measures. From a clinical outcomes perspective, 
composite scores (such as EDSS) are being rethought, and meas-
ures of more specific functions developed. Linking MRI measures 
and clinical outcomes remains challenging, but insights from con-
nectomics studies are helping to bridge the gap.
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